DHFR: A Drug Target / Disease Biomarker (G1719)

Target Name: DHFR

NCBI ID: G1719

DHFR: A Drug Target / Disease Biomarker

DHFR (Dihydroorotate Hydrate Form) is a drug target and a biomarker that is being studied for its potential in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. DHFR is a protein that is expressed in many different tissues and cells in the body, including the brain, spinal cord, and gastrointestinal tract. It is involved in the regulation of many different cellular processes, including cell signaling, cell division, and cell survival.

One of the main reasons for the interest in DHFR is its potential as a drug target. DHFR has been shown to be involved in many different signaling pathways, including the TGF-β pathway, the PI3K pathway, and the NF-kappa-B pathway. These pathways are involved in many different cellular processes, including cell growth, differentiation, and survival. By targeting DHFR, researchers hope to be able to inhibit these signaling pathways and prevent the development of cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, DHFR has also been shown to be a potential biomarker. By analyzing the levels of DHFR in different tissues and cells, researchers have been able to detect the presence of disease and monitor the effectiveness of treatments. For example, studies have shown that increasing the levels of DHFR in cancer cells can inhibit their growth and spread. Similarly, reducing the levels of DHFR in neurodegenerative disease cells has been shown to slow down the progression of the disease.

Another promising aspect of DHFR is its potential to be used in combination with other treatments. Because DHFR is involved in many different cellular processes, it may be able to be used in combination with other treatments to achieve greater effects. For example, studies have shown that DHFR can be used in combination with chemotherapy to improve the effectiveness of the treatment in cancer cells.

DHFR is also a potential target for new therapies because of its expression in many different tissues and cells. This makes it less likely to be affected by some of the common side effects associated with other treatments, such as damage to healthy tissues. Additionally, because DHFR is involved in many different signaling pathways, it may be able to be targeted by small molecules, which can be more effective than traditional therapies.

In conclusion, DHFR is a drug target and biomarker that has the potential to treat a wide range of diseases. Its involvement in many different cellular processes makes it an attractive target for new therapies, and its potential as a biomarker makes it an important tool for diagnosing and monitoring disease. Further research is needed to fully understand the effects of DHFR and to develop safe and effective treatments.

Protein Name: Dihydrofolate Reductase

Functions: Key enzyme in folate metabolism. Contributes to the de novo mitochondrial thymidylate biosynthesis pathway. Catalyzes an essential reaction for de novo glycine and purine synthesis, and for DNA precursor synthesis. Binds its own mRNA and that of DHFR2

More Common Targets